These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 35653145)

  • 41. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R; Liu MC; Yau C; Shatsky R; Pusztai L; Wallace A; Chien AJ; Forero-Torres A; Ellis E; Han H; Clark A; Albain K; Boughey JC; Jaskowiak NT; Elias A; Isaacs C; Kemmer K; Helsten T; Majure M; Stringer-Reasor E; Parker C; Lee MC; Haddad T; Cohen RN; Asare S; Wilson A; Hirst GL; Singhrao R; Steeg K; Asare A; Matthews JB; Berry S; Sanil A; Schwab R; Symmans WF; van 't Veer L; Yee D; DeMichele A; Hylton NM; Melisko M; Perlmutter J; Rugo HS; Berry DA; Esserman LJ
    JAMA Oncol; 2020 May; 6(5):676-684. PubMed ID: 32053137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
    J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.
    Jiang H; Zhong J; Wang J; Song G; Di L; Shao B; Zhang R; Liu Y; Zhu A; Wang N; Li H
    Cancer Med; 2024 May; 13(10):e7249. PubMed ID: 38770648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer.
    Sheffield KM; Peachey JR; Method M; Grimes BR; Brown J; Saverno K; Sugihara T; Cui ZL; Lee KT
    Future Oncol; 2022 Jul; 18(21):2667-2682. PubMed ID: 35611679
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial.
    Ahn HK; Sim SH; Suh KJ; Kim MH; Jeong JH; Kim JY; Lee DW; Ahn JH; Chae H; Lee KH; Kim JH; Lee KS; Sohn JH; Choi YL; Im SA; Jung KH; Park YH
    JAMA Oncol; 2022 Sep; 8(9):1271-1277. PubMed ID: 35797012
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and Safety of Weekly Paclitaxel With or Without Oral Alisertib in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.
    O'Shaughnessy J; McIntyre K; Wilks S; Ma L; Block M; Andorsky D; Danso M; Locke T; Scales A; Wang Y
    JAMA Netw Open; 2021 Apr; 4(4):e214103. PubMed ID: 33877311
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
    Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT
    Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
    Gluz O; Nitz UA; Christgen M; Kuemmel S; Holtschmidt J; Schumacher J; Hartkopf A; Potenberg J; Lüedtke-Heckenkamp K; Just M; Schem C; von Schumann R; Kolberg-Liedtke C; Eulenburg CZ; Schinköthe T; Graeser M; Wuerstlein R; Kates RE; Kreipe HH; Harbeck N
    JAMA Oncol; 2023 Jul; 9(7):946-954. PubMed ID: 37166817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial.
    Jackisch C; Stroyakovskiy D; Pivot X; Ahn JS; Melichar B; Chen SC; Meyenberg C; Al-Sakaff N; Heinzmann D; Hegg R
    JAMA Oncol; 2019 May; 5(5):e190339. PubMed ID: 30998824
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
    Gnant M; Dueck AC; Frantal S; Martin M; Burstein HJ; Greil R; Fox P; Wolff AC; Chan A; Winer EP; Pfeiler G; Miller KD; Colleoni M; Suga JM; Rubovsky G; Bliss JM; Mayer IA; Singer CF; Nowecki Z; Hahn O; Thomson J; Wolmark N; Amillano K; Rugo HS; Steger GG; Hernando Fernández de Aránguiz B; Haddad TC; Perelló A; Bellet M; Fohler H; Metzger Filho O; Jallitsch-Halper A; Solomon K; Schurmans C; Theall KP; Lu DR; Tenner K; Fesl C; DeMichele A; Mayer EL;
    J Clin Oncol; 2022 Jan; 40(3):282-293. PubMed ID: 34874182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B; Yau C; Campbell MJ; Yoshimatsu TF; Chien AJ; Wallace AM; Forero-Torres A; Pusztai L; Ellis ED; Albain KS; Blaes AH; Haley BB; Boughey JC; Elias AD; Clark AS; Isaacs CJ; Nanda R; Han HS; Yung RL; Tripathy D; Edmiston KK; Viscusi RK; Northfelt DW; Khan QJ; Asare SM; Wilson A; Hirst GL; Lu R; Symmans WF; Yee D; DeMichele AM; van 't Veer LJ; Esserman LJ; Olopade OI
    JAMA Netw Open; 2023 Dec; 6(12):e2349646. PubMed ID: 38153734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
    Harbeck N; Nitz UA; Christgen M; Kümmel S; Braun M; Schumacher C; Potenberg J; Tio J; Aktas B; Forstbauer H; Grischke EM; Scheffen I; Malter W; von Schumann R; Just M; Zu Eulenburg C; Biehl C; Kolberg-Liedtke C; Deurloo R; de Haas S; Jóźwiak K; Hauptmann M; Kates R; Graeser M; Wuerstlein R; Kreipe HH; Gluz O;
    J Clin Oncol; 2023 Aug; 41(22):3796-3804. PubMed ID: 36809046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Orozco Leal G; Armstrong N; Kernohan A; Ahmadu C; Coughlan D; McDermott K; Duffy S; O'Meara S; Robinson T; Vale L; Kleijnen J
    Pharmacoeconomics; 2023 Jul; 41(7):741-750. PubMed ID: 36952138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.
    Goetz MP; Toi M; Huober J; Sohn J; Trédan O; Park IH; Campone M; Chen SC; Manso LM; Paluch-Shimon S; Freedman OC; O'Shaughnessy J; Pivot X; Tolaney SM; Hurvitz SA; Llombart-Cussac A; André V; Saha A; van Hal G; Shahir A; Iwata H; Johnston SRD
    Ann Oncol; 2024 Aug; 35(8):718-727. PubMed ID: 38729566
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial.
    Buzdar AU; Suman VJ; Meric-Bernstam F; Leitch AM; Ellis MJ; Boughey JC; Unzeitig GW; Royce ME; Hunt KK
    JAMA Oncol; 2019 Jan; 5(1):45-50. PubMed ID: 30193295
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
    Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
    Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Martin M; Holmes FA; Ejlertsen B; Delaloge S; Moy B; Iwata H; von Minckwitz G; Chia SKL; Mansi J; Barrios CH; Gnant M; Tomašević Z; Denduluri N; Šeparović R; Gokmen E; Bashford A; Ruiz Borrego M; Kim SB; Jakobsen EH; Ciceniene A; Inoue K; Overkamp F; Heijns JB; Armstrong AC; Link JS; Joy AA; Bryce R; Wong A; Moran S; Yao B; Xu F; Auerbach A; Buyse M; Chan A;
    Lancet Oncol; 2017 Dec; 18(12):1688-1700. PubMed ID: 29146401
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
    Fasching PA; Hack CC; Nabieva N; Maass N; Aktas B; Kümmel S; Thomssen C; Wolf C; Kolberg HC; Brucker C; Janni W; Dall P; Schneeweiss A; Marme F; Sütterlin MW; Ruebner M; Theuser AK; Kellner S; Hofmann NM; Böhm S; Almstedt K; Lück HJ; Schmatloch S; Kalder M; Uleer C; Jurhasz-Böss I; Hanf V; Jackisch C; Müller V; Rack B; Belleville E; Wallwiener D; Rody A; Rauh C; Bayer CM; Uhrig S; Goossens C; Huebner H; Brucker SY; Hein A; Fehm TN; Häberle L
    Eur J Cancer; 2024 Sep; 209():114239. PubMed ID: 39059184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.